Announcing the 2nd Summit on Gastrointestinal Malignancies by DAVA Oncology! Join us this September to explore the latest data and emerging strategies in gastric, colorectal, pancreatic, and hepatobiliary cancer. Keep your 👀 peeled on our socials for a sneak peek of what’s to come. Check out the website to view the confirmed faculty and register to attend LIVE! https://lnkd.in/geR4ysK9
DAVA Oncology’s Post
More Relevant Posts
-
Navigating the challenges for differential diagnosis of IgM monoclonal gammopathy, a case report detailing very long-term survival of glioblastoma and a review exploring how exosomal miRNA can promote or inhibit colorectal cancer progression. Read the editor highlights from the Oncology Management journals: https://bit.ly/3Yqvx0K
-
Our team is looking forward to connecting with leading clinicians and researchers and to discussing the latest progress in #GIcancer at the ESMO - European Society for Medical Oncology Gastrointestinal Cancers Congress. Ulixertinib, our highly selective, first-in-class ERK 1/2 inhibitor, is being evaluated in combination with hydroxychloroquine in individuals with advanced gastrointestinal malignancies, including cholangiocarcinoma, pancreatic adenocarcinoma, colorectal adenocarcinoma, esophageal adenocarcinoma, and gastric adenocarcinoma. Learn more about the study: https://lnkd.in/eNbpDbJW #ESMOGI24 #MAPK
-
-
Last week, our CEO Ben Zeskind, Ph.D. sat down with Caroline Hopkins at Precision Oncology News, to discuss the recent progress with our lead product candidate, IMM-1-104. From IMM-1-104's fast-track designation for patients with pancreatic cancer who have failed one line of treatment, to dosing our first patient in the Phase 2 portion of the ongoing IMM-1-104 Phase 1/2a clinical trial, to reporting positive preliminary data from the Phase 1 portion of that trial Read more about our differentiated approach to cancer research and next steps with IMM-1-104.https://buff.ly/4cvtRd2
Precision Oncology News (@PrecOncNews) on X
twitter.com
-
How is it that pancreatic cancer is so resistant to radiation..? Check out the latest episode of Science Dose, featuring Dr. Yaacov Lawrence discussing the above question and new ways to increase radiotherapeutic efficacy.
At Sheba, we remain committed to pushing the boundaries of medical science and ensuring that patients worldwide can find hope for healing. I am pleased to share the latest episode of 'Science Dose,' where Dr. Yaacov Lawrence, Director of Sheba’s Radiation Oncology Department, sheds light on the intricacies of treating pancreatic cancer and discusses a pioneering drug therapy set to increase radiotherapeutic efficacy. I invite you to watch the video and learn more.
-
2023 updated MASCC and ESMO - European Society for Medical Oncology recommendations for prophylaxis of nausea and vomiting - Erman Akkus, MD The Multinational Association of Supportive Care in Cancer (MASCC) #Aprepitant #Cancer #Cisplatin #Dexamethasone #ESMO #MASCC #Olanzapin #OncoDaily #Oncology
Erman Akkus: 2023 updated MASCC and ESMO recommendations for prophylaxis of nausea and vomiting - Oncodaily | Oncology News, Insights, Stories
oncodaily.com
-
ESMO23 - Advances in EGFR mutated NSCLC - Amalya Sargsyan ESMO - European Society for Medical Oncology #Amivantamab #Cancer #ESMO23 #MedicalOncology #OncoDaily #Oncology #ResearchFellow
Amalya Sargsyan: ESMO23 - Advances in EGFR mutated NSCLC - Oncodaily | Oncology News, Insights, Stories
oncodaily.com
-
What is the optimal way of effective drug development for ultra-rare cancers? - Shushan Hovsepyan Ralf Herold Pan Pantziarka Kathrin Schuster Francesco Pignatti Bernd Kasper OncoDaily #ASPS #Cancer #JournalOfClinical #Oncology #OncoDaily #Hematology #OncologyCenter
Shushan Hovsepyan: What is the optimal way of effective drug development for ultra-rare cancers? - OncoDaily
oncodaily.com
-
Out in JCO the groundbreaking results of the randomized phase 3 trial PALOMA-3 study Antonio Passaro American Society of Clinical Oncology (ASCO) #ASCO24 #Cancer #NSCLC #LCsm #ClinicalTrials #OncoDaily #Oncology
Out in JCO the groundbreaking results of the randomized phase 3 trial PALOMA-3 study - OncoDaily
oncodaily.com
